PSA: what your result means.

A prostate-specific protein used for prostate cancer screening in men. PSA is measured by blood test as part of the CatastrophicScreen panel in the HodieLabs Health Blueprint.

Note: this biomarker is measured and interpreted for males; reference ranges are sex-specific.

Note: this is an optional biomarker in the HodieLabs panel, included based on individual risk profile and preference after doctor discussion.

Why PSA matters

GOVERNANCE: PSA screening requires a clearly governed shared-decision framework. USPSTF supports individualised PSA-based screening mainly for men aged 55–69, and recommends against routine PSA screening for men aged 70+. USPSTF stresses the risks of false positives, overdiagnosis, and treatment harms. PSA should never appear as a generic "longevity optimisation" biomarker.

Associated risks when out of range: Elevated PSA may indicate prostate cancer, benign prostatic hyperplasia, or prostatitis, PSA is organ-specific but not cancer-specific, most elevations are benign.

What the clinical evidence shows

The evidence base behind how the HodieLabs Evidence-Based Clinical Library interprets PSA, from randomised trials, prospective cohorts and genetic (Mendelian randomisation) studies. Full citations in the reference list below.

• ERSPC trial (Schröder et al. NEJM 2009): PSA screening reduced prostate cancer mortality by ~20% in ~182,000 European men, but with substantial overdiagnosis, which is why informed, risk-based testing has replaced blanket screening.
• PLCO trial (Andriole et al. NEJM 2009): the parallel US trial showed no mortality benefit amid high background testing. Together the trials define the honest trade-off every man should understand before a PSA test.

Evidence-based reference ranges

The HodieLabs Evidence-Based Clinical Library interprets PSA against published clinical authority standards, never arbitrary "optimal" ranges. Measured in µg/L (ng/mL):

Clinical interpretation

• GOVERNANCE: PSA screening requires a clearly governed shared-decision framework. USPSTF supports individualised PSA-based screening mainly for men aged 55–69, and recommends against routine PSA screening for men aged 70+.
• USPSTF stresses the risks of false positives, overdiagnosis, and treatment harms. PSA should never appear as a generic "longevity optimisation" biomarker.
• PSA is organ-specific but not cancer-specific. Most elevations are benign (BPH, prostatitis).
• PSA velocity (rate of change over time) is more informative than a single reading.
• PSA >4.0 µg/L or rapidly rising PSA warrants urology referral.
• Optional; requires informed consent, shared decision-making, and an appropriate follow-up pathway before inclusion in any screening panel.

What improves it: the evidence-based levers

• PSA velocity (rate of change over time) is more informative than a single reading
• PSA >4.0 µg/L or rapidly rising PSA warrants urology referral

Recommended testing frequency: Annual, as part of a comprehensive panel. Single markers are always interpreted in context.

How PSA testing works at HodieLabs

PSA is measured in every Health Blueprint at our Melbourne Preventative Health & Longevity Clinic, interpreted by a doctor against the guideline-cited ranges above and tracked over time through your HodieLabs membership.

References

1. Schröder FH, et al. Screening and prostate-cancer mortality in a randomized European study (ERSPC). N Engl J Med. 2009;360:1320–1328.
2. Andriole GL, et al. Mortality results from a randomized prostate-cancer screening trial (PLCO). N Engl J Med. 2009;360:1310–1319.

This page is general information from the HodieLabs Evidence-Based Clinical Library, not medical advice. Speak with your GP about what testing and care is appropriate for you.